AGCO
AGCO (NYSE: AGCO), a worldwide manufacturer and distributor of agricultural equipment, today unveiled IDEAL, its new top range combine harvester, in Breganze, Italy. “The IDEAL combine is the result of many years of R&D, countless engineering hours, committed teamwork, and leading industry expertise,” said Martin Richenhagen, AGCO Chairman, President and CEO. “It is yet another result of AGCO’s tireless efforts to deliver the most innovative solutions to farmers feeding the world.”
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170905005414/en/
The development of the IDEAL combine is also a significant step to continuously strengthen AGCO’s global harvesting offering and to solidify AGCO’s position as the leading full line manufacturer of agricultural solutions.
The new generation of combines is the result of a global “Voice of Customer” study. The findings showed that there is a need for an entirely new combine platform, prompting AGCO’s R&D team to start from a “blank sheet of paper.”
A global team from different AGCO sites developed the features customers had pointed out in the study. “IDEAL is part of AGCO’s global platform strategy that supports synergies across different regions, saves cost, and optimizes supply chain management. Like AGCO’s Global Series tractors, this combine platform expresses our commitment to brand-new designs, and to practical solutions that empower farmers across the world to be more productive and to feed a growing world population,” said Eric Hansotia, Senior Vice President, Global Crop Cycle & Fuse Connected Services.
Close to 50 combine prototypes were built and tested in the lab, on the field and around the globe in varying environments to develop a unique combine that is able to be used for all crops and operate in all conditions, in all parts of the world.
“Our customers harvest in many different conditions, and each farm has a unique set of requirements for their operation,” continued Hansotia. “The IDEAL combine aims at exceeding our customers’ needs and expectations. It is the most innovative combine we have ever produced and an investment in the future of harvesting. IDEAL will change the way harvesting is done today.”
At the heart of the IDEAL combine is an efficient processing system which outperforms on grain and straw quality, grain handling, power efficiency, and capacity in a wide variety of conditions.
The IDEAL combine features the latest patented innovations from AGCO’s Fuse Connected Services division, is fully connected, offers an automated combine adjustment system, and Real Time Crop Flow visualization.
IDEAL stands for ease of use and optimizing complex harvesting operations by providing the efficiency, visibility and the comfort farmers need on the field.
IDEAL is the first high capacity combine of its kind with such a narrow body and unique for its impressive design. IDEAL is designed for convenient road transportation.
IDEAL will be available in three of AGCO’s core brands: Challenger, Fendt and Massey Ferguson and will debut at Agritechnica in November 2017.
The new combine will be launched into different markets in 2018. IDEAL will be offered in 3 different models, 7, 8 and 9, will be available with tires or tracks, and also in ParaLevel version.
For more information about the product, please see the Fendt press release and the Massey Ferguson press release.
Fendt: http://www.fendt.com/int/news-center.html
Massey Ferguson: http://int.masseyferguson.com/press-centre.aspx
About AGCO
AGCO (NYSE: AGCO) is a global leader in the design, manufacture and distribution of agricultural solutions and supports more productive farming through its full line of equipment and related services. AGCO products are sold through five core brands, Challenger®, Fendt®, GSI®, Massey Ferguson® and Valtra®, supported by Fuse® precision technologies and farm optimization services, and are distributed globally through a combination of over 3,000 independent dealers and distributors in more than 150 countries. Founded in 1990, AGCO is headquartered in Duluth, GA, USA. In 2016, AGCO had net sales of $7.4 billion. For more information, visit http://www.AGCOcorp.com . For company news, information and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005414/en/
Contact:
AGCO
Sepp Nuscheler, +49834277343
Josef.Nuscheler@agcocorp.com
or
Paul
Lay, +442476851209
Paul.Lay@agcocorp.com
or
Abby
Burton, +17708136167
Abby.Burton@agcocorp.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom